Abstract
The microtubule-associated protein tau (τ) is a phosphoprotein that is crucial for regulating microtubule dynamics. Tau is highly enriched in neurons, where it functions by binding tubulin and stabilizing axonal microtubules. Phosphorylation of tau within its microtubule-binding repeat (R) domains significantly reduces its affinity for tubulin, leading to a loss in microtubule stability. In neurons, dysregulated kinase activity often results in the formation of hyper-phosphorylated tau isoforms that remain permanently detached from microtubules. If left untreated, hyper-phosphorylated tau can aggregate into insoluble, prion-like oligomers that contribute to the pathogenesis of neurodegenerative disease. Consequently, there is considerable interest in developing inhibitors that reduce levels of hyper-phosphorylated tau in neurons. In this study, we have generated a synthetic peptide mimetic (tR1) of the tau R1 domain as an inhibitor of microtubule-affinity regulating kinase 2 (MARK2). In vitro assays showed that tR1 inhibits the MARK2-mediated phosphorylation of tau within its R1 domain at Ser262, a residue critical for favorable tau-tubulin interactions. We also demonstrate that tR1 peptides are > 90% stable up to 24 h in neurobasal medium and RPMI media supplemented with human serum. Uptake experiments in cultured rat primary cortical neurons indicate that tR1 is internalized through an energy-dependent mechanism and can be delivered to the cytoplasm when co-treated with bafilomycin A1 or chloroquine. Furthermore, we show tR1 inhibits phosphorylation of endogenous tau at Ser262 in cultured neurons following activation of intracellular kinases. This inhibitory effect was selective for kinases that phosphorylate tau at Ser262, as tR1 did not inhibit tau phosphorylation at Thr231. Collectively, these results establish tR1 as a highly-stable, peptide-based kinase inhibitor that reduces the level of phosphorylated tau proteins in neurons.
Similar content being viewed by others
References
Alonso AD, Di Clerico J, Li B, Corbo CP, Alaniz ME, Grundke-Iqbal I, Iqbal K (2010) Phosphorylation of tau at Thr212, Thr231, and Ser262 combined causes neurodegeneration. J Biol Chem 285:30851–30860
Balaban CL, Banchio C, Ceccarelli EA (2017) TAT-mediated transduction of bacterial redox proteins generates a cytoprotective effect on neuronal cells. PLoS ONE 12:e0184617
Beharry C, Cohen LS, Di J, Ibrahim K, Briffa-Mirabella S, Adel A C (2014) Tau-induced neurodegeneration: mechanisms and targets. Neurosci Bull 30:346–358
Biernat J, Wu YZ, Timm T, Zheng-Fischhofer Q, Mandelkow E, Meijer L, Mandelkow EM (2002) Protein kinase MARK/PAR-1 is required for neurite outgrowth and establishment of neuronal polarity. Mol Biol Cell 13:4013–4028
Britto PJ, Knipling L, McPhie P, Wolff J (2005) Thiol-disulphide interchange in tubulin: kinetics and the effect on polymerization. Biochem J 389:549–558
Caron NJ, Quenneville SP, Tremblay JP (2004) Endosome disruption enhances the functional nuclear delivery of Tat-fusion proteins. Biochem Biophys Res Commun 319:12–20
Carpenter EL, Haglund EA, Mace EM, Deng D, Martinez D, Wood AC, Chow AK, Weiser DA, Belcastro LT, Winter C, Bresler SC, Vigny M, Mazot P, Asgharzadeh S, Seeger RC, Zhao H, Guo R, Christensen JG, Orange JS, Pawel BR, Lemmon MA, Mosse YP (2012) Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma. Oncogene 31:4859–4867
Cheung ZH, Ip NY (2012) Cdk5: a multifaceted kinase in neurodegenerative diseases. Trends Cell Biol 22:169–175
Cho JH, Johnson GV (2004) Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3beta (GSK3beta) plays a critical role in regulating tau’s ability to bind and stabilize microtubules. J Neurochem 88:349–358
Colvin RA, Lai B, Holmes WR, Lee D (2015) Understanding metal homeostasis in primary cultured neurons. Studies using single neuron subcellular and quantitative metallomics. Metallomics 7:1111–1123
Csokova N, Skrabana R, Liebig HD, Mederlyova A, Kontsek P, Novak M (2004) Rapid purification of truncated tau proteins: model approach to purification of functionally active fragments of disordered proteins, implication for neurodegenerative diseases. Protein Expr Purif 35:366–372
Dehmelt L, Halpain S (2005) The MAP2/Tau family of microtubule-associated proteins. Genome Biol 6:204
Drewes G, Ebneth A, Preuss U, Mandelkow EM, Mandelkow E (1997) MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption. Cell 89:297–308
Eldar-Finkelman H, Eisenstein M (2009) Peptide inhibitors targeting protein kinases. Curr Pharm Des 15:2463–2470
Elkins JM, Fedele V, Szklarz M, Abdul Azeez KR, Salah E, Mikolajczyk J, Romanov S, Sepetov N, Huang XP, Roth BL, Al Haj Zen A, Fourches D, Muratov E, Tropsha A, Morris J, Teicher BA, Kunkel M, Polley E, Lackey KE, Atkinson FL, Overington JP, Bamborough P, Muller S, Price DJ, Willson TM, Drewry DH, Knapp S, Zuercher WJ (2016) Comprehensive characterization of the published kinase inhibitor set. Nat Biotechnol 34:95–103
Farkhani SM, Valizadeh A, Karami H, Mohammadi S, Sohrabi N, Badrzadeh F (2014) Cell penetrating peptides: efficient vectors for delivery of nanoparticles, nanocarriers, therapeutic and diagnostic molecules. Peptides 57:78–94
Fields GB, Noble RL (1990) Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res 35:161–214
Gallion SL, Qian D (2005) Chemical genetic approaches to kinase drug discovery. Curr Opin Drug Discov Dev 8:638–645
Garuti L, Roberti M, Bottegoni G (2010) Non-ATP competitive protein kinase inhibitors. Curr Med Chem 17:2804–2821
Gibbs KL, Greensmith L, Schiavo G (2015) Regulation of axonal transport by protein kinases. Trends Biochem Sci 40:597–610
Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA (1989) Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer’s disease. Neuron 3:519–526
Gu GJ, Lund H, Wu D, Blokzijl A, Classon C, von Euler G, Landegren U, Sunnemark D, Kamali-Moghaddam M (2013a) Role of individual MARK isoforms in phosphorylation of tau at Ser262 in Alzheimer’s disease. Neuromol Med 15:458–469
Gu GJ, Wu D, Lund H, Sunnemark D, Kvist AJ, Milner R, Eckersley S, Nilsson LN, Agerman K, Landegren U, Kamali-Moghaddam M (2013b) Elevated MARK2-dependent phosphorylation of Tau in Alzheimer’s disease. J Alzheimers Dis 33:699–713
Gundry C, Marco S, Rainero E, Miller B, Dornier E, Mitchell L, Caswell PT, Campbell AD, Hogeweg A, Sansom OJ, Morton JP, Norman JC (2017) Phosphorylation of Rab-coupling protein by LMTK3 controls Rab14-dependent EphA2 trafficking to promote cell:cell repulsion. Nat Commun 8:14646
Han KC, Kim SY, Yang EG (2012) Recent advances in designing substrate-competitive protein kinase inhibitors. Curr Pharm Des 18:2875–2882
Hughes JN, Wong CK, Lau KX, Rathjen PD, Rathjen J (2014) Regulation of pluripotent cell differentiation by a small molecule, staurosporine. Differentiation 87:101–110
Hurov J, Piwnica-Worms H (2007) The Par-1/MARK family of protein kinases: from polarity to metabolism. Cell Cycle 6:1966–1969
Inoue H, Hiradate Y, Shirakata Y, Kanai K, Kosaka K, Gotoh A, Fukuda Y, Nakai Y, Uchida T, Sato E, Tanemura K (2014) Site-specific phosphorylation of tau protein is associated with deacetylation of microtubules in mouse spermatogenic cells during meiosis. FEBS Lett 588:2003–2008
Jenkins SM, Johnson GV (1999) Modulation of tau phosphorylation within its microtubule-binding domain by cellular thiols. J Neurochem 73:1843–1850
Jenkins SM, Johnson GV (2000) Microtubule/MAP-affinity regulating kinase (MARK) is activated by phenylarsine oxide in situ and phosphorylates tau within its microtubule-binding domain. J Neurochem 74:1463–1468
Jenssen H, Aspmo SI (2008) Serum stability of peptides. Methods Mol Biol 494:177–186
Johnson LN (2009) The regulation of protein phosphorylation. Biochem Soc Trans 37:627–641
Kaidanovich-Beilin O, Eldar-Finkelman H (2006) Peptides targeting protein kinases: strategies and implications. Physiology (Bethesda) 21:411–418
Kandimalla KK, Scott OG, Fulzele S, Davidson MW, Poduslo JF (2009) Mechanism of neuronal versus endothelial cell uptake of Alzheimer’s disease amyloid β protein. PLoS ONE 4:e4627
Karikari TK, Turner A, Stass R, Lee LC, Wilson B, Nagel DA, Hill EJ, Moffat KG (2017) Expression and purification of tau protein and its frontotemporal dementia variants using a cleavable histidine tag. Protein Expr Purif 130:44–54
Keenan S, Wetherill SJ, Ugbode CI, Chawla S, Brackenbury WJ, Evans GJ (2017) Inhibition of N1-Src kinase by a specific SH3 peptide ligand reveals a role for N1-Src in neurite elongation by L1-CAM. Sci Rep 7:43106
Li Y, Xie W, Fang G (2008) Fluorescence detection techniques for protein kinase assay. Anal Bioanal Chem 390:2049–2057
Liou JS, Liu BR, Martin AL, Huang YW, Chiang HJ, Lee HJ (2012) Protein transduction in human cells is enhanced by cell-penetrating peptides fused with an endosomolytic HA2 sequence. Peptides 37:273–284
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265–275
Madani F, Abdo R, Lindberg S, Hirose H, Futaki S, Langel U, Graslund A (2013) Modeling the endosomal escape of cell-penetrating peptides using a transmembrane pH gradient. Biochim Biophys Acta 1828:1198–1204
Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298:1912–1934
Martin KJ, Arthur JS (2012) Selective kinase inhibitors as tools for neuroscience research. Neuropharmacology 63:1227–1237
Matenia D, Griesshaber B, Li XY, Thiessen A, Johne C, Jiao J, Mandelkow E, Mandelkow EM (2005) PAK5 kinase is an inhibitor of MARK/Par-1, which leads to stable microtubules and dynamic actin. Mol Biol Cell 16:4410–4422
McDonald JA (2014) Canonical and noncanonical roles of Par-1/MARK kinases in cell migration. Int Rev Cell Mol Biol 312:169–199
Mephon-Gaspard A, Boca M, Pioche-Durieu C, Desforges B, Burgo A, Hamon L, Pietrement O, Pastre D (2016) Role of tau in the spatial organization of axonal microtubules: keeping parallel microtubules evenly distributed despite macromolecular crowding. Cell Mol Life Sci 73:3745–3760
Mietelska-Porowska A, Wasik U, Goras M, Filipek A, Niewiadomska G (2014) Tau protein modifications and interactions: their role in function and dysfunction. Int J Mol Sci 15:4671–4713
Mukherji M (2005) Phosphoproteomics in analyzing signaling pathways. Expert Rev Proteom 2:117–128
Musi N (2006) AMP-activated protein kinase and type 2 diabetes. Curr Med Chem 13:583–589
Palasek SA, Cox ZJ, Collins JM (2007) Limiting racemization and aspartimide formation in microwave-enhanced Fmoc solid phase peptide synthesis. J Pept Sci 13:143–148
Qi H, Prabakaran S, Cantrelle FX, Chambraud B, Gunawardena J, Lippens G, Landrieu I (2016) Characterization of neuronal tau protein as a target of extracellular signal-regulated kinase. J Biol Chem 291:7742–7753
Russo I, Berti G, Plotegher N, Bernardo G, Filograna R, Bubacco L, Greggio E (2015) Leucine-rich repeat kinase 2 positively regulates inflammation and down-regulates NF-kappaB p50 signaling in cultured microglia cells. J Neuroinflamm 12:230
Sato AK, Viswanathan M, Kent RB, Wood CR (2006) Therapeutic peptides: technological advances driving peptides into development. Curr Opin Biotechnol 17:638–642
Sato K, Nagai J, Mitsui N, Ryoko Y, Takano M (2009) Effects of endocytosis inhibitors on internalization of human IgG by Caco-2 human intestinal epithelial cells. Life Sci 85:800–807
Scapin G (2006) Protein kinase inhibition: different approaches to selective inhibitor design. Curr Drug Targets 7:1443–1454
Schenk PW, Snaar-Jagalska BE (1999) Signal perception and transduction: the role of protein kinases. Biochim Biophys Acta 1449:1–24
Schneider CA, Rasband WS, Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9:671–675
Schwalbe M, Biernat J, Bibow S, Ozenne V, Jensen MR, Kadavath H, Blackledge M, Mandelkow E, Zweckstetter M (2013) Phosphorylation of human tau protein by microtubule affinity-regulating kinase 2. Biochemistry 52:9068–9079
Shiraishi T, Nielsen PE (2006) Enhanced delivery of cell-penetrating peptide-peptide nucleic acid conjugates by endosomal disruption. Nat Protoc 1:633–636
Sironi JJ, Yen SH, Gondal JA, Wu Q, Grundke-Iqbal I, Iqbal K (1998) Ser-262 in human recombinant tau protein is a markedly more favorable site for phosphorylation by CaMKII than PKA or PhK. FEBS Lett 436:471–475
Sreelatha A, Kinch LN, Tagliabracci VS (2015) The secretory pathway kinases. Biochim Biophys Acta 1854:1687–1693
Stephenson SA, Douglas EL, Mertens-Walker I, Lisle JE, Maharaj MS, Herington AC (2015) Anti-tumour effects of antibodies targeting the extracellular cysteine-rich region of the receptor tyrosine kinase EphB4. Oncotarget 6:7554–7569
Tassan JP, Le Goff X (2004) An overview of the KIN1/PAR-1/MARK kinase family. Biol Cell 96:193–199
Tejeda-Munoz N, Robles-Flores M (2015) Glycogen synthase kinase 3 in Wnt signaling pathway and cancer. IUBMB Life 67:914–922
Timm T, Matenia D, Li XY, Griesshaber B, Mandelkow EM (2006) Signaling from MARK to tau: regulation, cytoskeletal crosstalk, and pathological phosphorylation. Neurodegener Dis 3:207–217
Timm T, Marx A, Panneerselvam S, Mandelkow E, Mandelkow EM (2008a) Structure and regulation of MARK, a kinase involved in abnormal phosphorylation of tau protein. BMC Neurosci 9(Suppl 2):S9
Timm T, Balusamy K, Li X, Biernat J, Mandelkow E, Mandelkow EM (2008b) Glycogen synthase kinase (GSK) 3beta directly phosphorylates Serine 212 in the regulatory loop and inhibits microtubule affinity-regulating kinase (MARK) 2. J Biol Chem 283:18873–18882
Timm T, von Kries JP, Li X, Zempel H, Mandelkow E, Mandelkow EM (2011) Microtubule affinity regulating kinase activity in living neurons was examined by a genetically encoded fluorescence resonance energy transfer/fluorescence lifetime imaging-based biosensor: inhibitors with therapeutic potential. J Biol Chem 286:41711–41722
Tolstikov VV, Cole R, Fang H, Pincus SH (1997) Influence of endosome-destabilizing peptides on efficacy of anti-HIV immunotoxins. Bioconjug Chem 8:38–43
Trentini DB, Suskiewicz MJ, Heuck A, Kurzbauer R, Deszcz L, Mechtler K, Clausen T (2016) Arginine phosphorylation marks proteins for degradation by a Clp protease. Nature 539:48–53
Wang JZ, Xia YY, Grundke-Iqbal I, Iqbal K (2013) Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration. J Alzheimers Dis 33(Suppl 1):S123–S139
Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW (1975) A protein factor essential for microtubule assembly. Proc Natl Acad Sci USA 72:1858–1862
Yoshimori T, Yamamoto A, Moriyama Y, Futai M, Tashiro Y (1991) Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells. J Biol Chem 266:17707–17712
Zhu Q, Liang S, Martin L, Gasparini S, Menez A, Vita C (2002) Role of disulfide bonds in folding and activity of leiurotoxin I: just two disulfides suffice. Biochemistry 41:11488–11494
Zorzi A, Middendorp SJ, Wilbs J, Deyle K, Heinis C (2017) Acylated heptapeptide binds albumin with high affinity and application as tag furnishes long-acting peptides. Nature Commun 8:16092
Acknowledgements
This work was supported in part by the Department of Chemistry and Biochemistry, the Department of Biological Sciences, the Edison Biotechnology Institute, the College of Arts and Sciences, and the Vice President for Research at Ohio University. Additional funding for this research came from the Ohio Musculoskeletal and Neurological Institute (OMNI) and the Ohio University Research Counsel (proposal #17−15) at Ohio University. Author Najah Alqaeisoom was supported by the Saudi Arabian Cultural Mission (SACM, #397056). The authors would like to thank Professor Kevin G. Moffat for supplying the pProEX-HTa-Myc-K18 plasmid.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors confirm that there are no conflicts of interest.
Ethical Approval
The care and use of all animals used in this work adhered to the American Physiological Society’s Guiding Principles in the Care and Use of Animals. All experimental procedures utilized herein were approved by the Ohio University Institutional Animal Care and Use Committee. All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Alqaeisoom, N., Qian, C., Arachchige, D. et al. Inhibiting Phosphorylation of Tau (τ) Proteins at Ser262 Using Peptide-Based R1 Domain Mimetics. Int J Pept Res Ther 25, 447–463 (2019). https://doi.org/10.1007/s10989-018-9689-6
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10989-018-9689-6